Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patients with higher-atherothrombotic risk vs. lower-atherothrombotic risk undergoing coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials.
Hemetsberger R, Mankerious N, Toelg R, Abdelghani M, Farhan S, Garcia-Garica HM, Allali A, Windecker S, Lefèvre T, Saito S, Kandzari D, Waksman R, Richardt G. Hemetsberger R, et al. Among authors: farhan s. Clin Res Cardiol. 2023 Sep;112(9):1278-1287. doi: 10.1007/s00392-023-02205-4. Epub 2023 Apr 16. Clin Res Cardiol. 2023. PMID: 37062047 Clinical Trial.
Drug-eluting introducer sheath prevents local peripheral complications: pre-clinical evaluation of nitric oxide-coated sheath.
Hemetsberger R, Posa A, Farhan S, Hemetsberger H, Redwan B, Pavo N, Pavo IJ, Plass CA, Petnehazy O, Petrasi Z, Huber K, Glogar D, Maurer G, Gyöngyösi M. Hemetsberger R, et al. Among authors: farhan s. JACC Cardiovasc Interv. 2011 Jan;4(1):98-106. doi: 10.1016/j.jcin.2010.09.018. JACC Cardiovasc Interv. 2011. PMID: 21251636 Free article.
Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
Hengstenberg C, Chandrasekhar J, Sartori S, Lefevre T, Mikhail G, Meneveau N, Tron C, Jeger R, Kupatt C, Vogel B, Farhan S, Sorrentino S, Sharma M, Snyder C, Husser O, Boekstegers P, Hambrecht R, Widder J, Hildick-Smith D, De Carlo M, Wijngaard P, Deliargyris E, Bernstein D, Baber U, Mehran R, Anthopoulos P, Dangas G; BRAVO-3 Investigators. Hengstenberg C, et al. Among authors: farhan s. Catheter Cardiovasc Interv. 2017 Nov 15;90(6):1027-1037. doi: 10.1002/ccd.27155. Epub 2017 Jun 20. Catheter Cardiovasc Interv. 2017. PMID: 28493641 Clinical Trial.
Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
Linke A, Chandrasekhar J, Sartori S, Lefevre T, van Belle E, Schaefer U, Tchetche D, Sardella G, Webb J, Colombo A, Windecker S, Vogel B, Farhan S, Sorrentino S, Sharma M, Snyder C, Asgar A, Dumonteil N, Tamburino C, Hink U, Violini R, Stella P, Bernstein D, Deliargyris E, Hengstenberg C, Baber U, Mehran R, Anthopoulos P, Dangas G; BRAVO-3 Investigators. Linke A, et al. Among authors: farhan s. Catheter Cardiovasc Interv. 2017 Nov 15;90(6):1016-1026. doi: 10.1002/ccd.27154. Epub 2017 Jul 19. Catheter Cardiovasc Interv. 2017. PMID: 28498562 Clinical Trial.
Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.
Giustino G, Harari R, Baber U, Sartori S, Stone GW, Leon MB, Windecker S, Serruys PW, Kastrati A, Von Birgelen C, Kimura T, Stefanini GG, Dangas GD, Wijns W, Steg PG, Morice MC, Camenzind E, Weisz G, Smits PC, Sorrentino S, Sharma M, Farhan S, Faggioni M, Kandzari D, Galatius S, Jeger RV, Valgimigli M, Itchhaporia D, Mehta L, Kim HS, Chieffo A, Mehran R. Giustino G, et al. Among authors: farhan s. JAMA Cardiol. 2017 Aug 1;2(8):855-862. doi: 10.1001/jamacardio.2017.1978. JAMA Cardiol. 2017. PMID: 28658478 Free PMC article.
Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative.
Chandrasekhar J, Baber U, Sartori S, Stefanini GG, Sarin M, Vogel B, Farhan S, Camenzind E, Leon MB, Stone GW, Serruys PW, Wijns W, Steg PG, Weisz G, Chieffo A, Kastrati A, Windecker S, Morice MC, Smits PC, von Birgelen C, Mikhail GW, Itchhaporia D, Mehta L, Kim HS, Valgimigli M, Jeger RV, Kimura T, Galatius S, Kandzari D, Dangas G, Mehran R. Chandrasekhar J, et al. Among authors: farhan s. JACC Cardiovasc Interv. 2018 Jan 8;11(1):53-65. doi: 10.1016/j.jcin.2017.11.020. JACC Cardiovasc Interv. 2018. PMID: 29301648 Free article.
295 results